論文

査読有り
2013年1月

The F-prostaglandin receptor is a novel marker for tumor endothelial cells in renal cell carcinoma

PATHOLOGY INTERNATIONAL
  • Kosuke Akiyama
  • ,
  • Noritaka Ohga
  • ,
  • Nako Maishi
  • ,
  • Yasuhiro Hida
  • ,
  • Kazuko Kitayama
  • ,
  • Taisuke Kawamoto
  • ,
  • Takahiro Osawa
  • ,
  • Yuko Suzuki
  • ,
  • Nobuo Shinohara
  • ,
  • Katsuya Nonomura
  • ,
  • Masanobu Shindoh
  • ,
  • Kyoko Hida

63
1
開始ページ
37
終了ページ
44
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1111/pin.12031
出版者・発行元
WILEY-BLACKWELL

Tumor angiogenesis is necessary for tumor progression and metastasis; therefore, tumor blood vessels are potential therapeutic targets in anticancer therapy. We previously reported that tumor endothelial cells (TECs) exhibit different phenotypes compared with normal endothelial cells (NECs), and microarray analyses of mouse TECs and NECs have shown that several genes are upregulated in TECs compared with NECs. Among these genes, the expression levels of prostaglandin F receptor (PTGFR) mRNA, which encodes the prostaglandin F receptor (FP), were higher in TECs than in NECs. It has been reported that FP and its ligand, prostaglandin F2a, are involved in tumor angiogenesis. However, there have been no reports of the expression of PTGFR in the tumor vessels of renal cell carcinoma (RCC). Thus, we isolated human TECs (hTECs) from RCCs. The expression levels of PTGFR mRNA were also upregulated in hTECs. In addition, immunostaining showed that the PTGFR was expressed in human tumor blood vessels in vivo. These findings suggested that PTGFR is a novel TEC marker and that it may be a novel target for antiangiogenic therapy for RCC.

Web of Science ® 被引用回数 : 8

リンク情報
DOI
https://doi.org/10.1111/pin.12031
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/23356224
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000314223800005&DestApp=WOS_CPL

エクスポート
BibTeX RIS